Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Notes Payables (2016 - 2020)

Historic Notes Payables for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to $7.3 million.

  • Larimar Therapeutics' Notes Payables changed 0.0% to $7.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $7.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $7.3 million for FY2019, which is 3332.72% up from last year.
  • Larimar Therapeutics' Notes Payables amounted to $7.3 million in Q1 2020, which was down 0.0% from $7.3 million recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' Notes Payables ranged from a high of $20.5 million in Q3 2018 and a low of $1.3 million during Q3 2017
  • Moreover, its 5-year median value for Notes Payables was $7.3 million (2019), whereas its average is $8.3 million.
  • Over the last 5 years, Larimar Therapeutics' Notes Payables had its largest YoY gain of 151671.92% in 2018, and its largest YoY loss of 7272.5% in 2018.
  • Larimar Therapeutics' Notes Payables (Quarter) stood at $3.6 million in 2016, then skyrocketed by 457.26% to $20.0 million in 2017, then plummeted by 72.72% to $5.5 million in 2018, then surged by 33.33% to $7.3 million in 2019, then changed by 0.0% to $7.3 million in 2020.
  • Its last three reported values are $7.3 million in Q1 2020, $7.3 million for Q4 2019, and $7.3 million during Q3 2019.